Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

FLORHAM PARK, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company), a biotechnology company developing allogeneic cell therapies and biomaterial products, today announced that it closed two financing transactions totaling $21 million in gross proceed. As detailed in the Form 8-K filed by the Company, one of the two financing transactions is a securities purchase agreement with the Company's largest investor, Dragasac Limited ("Dragasac") providing for the private placement of ...